Methotrexate: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 14: | Line 14: | ||
Methotrexate has provided as a treatment option in clinical setting since the year 1948. Leukemia patients whom received folic acid, were observed to decline, while patients with restricted folic acid consumption improved, prompting experiments with analogs of folic acids. Methotrexate was originally developed from these observations suggesting that an analog of folic acid was able to cause a remission in symptoms of acute lymphoblastic leukemia in 1947. The subsequent derivation of a mechanism of action for methotrexate was developed and methotrexate was used for treatment of various cancerous even non-cancerous cases<ref>Methotrexate. (n.d.). UW Department of Orthopaedics and Sports Medicine - Patient Care. Retrieved March 10, 2011, from http://www.orthop.washington.edu/PatientCare/OurServices/Arthritis/Articles/Methotrexate.aspx </ref>. | Methotrexate has provided as a treatment option in clinical setting since the year 1948. Leukemia patients whom received folic acid, were observed to decline, while patients with restricted folic acid consumption improved, prompting experiments with analogs of folic acids. Methotrexate was originally developed from these observations suggesting that an analog of folic acid was able to cause a remission in symptoms of acute lymphoblastic leukemia in 1947. The subsequent derivation of a mechanism of action for methotrexate was developed and methotrexate was used for treatment of various cancerous even non-cancerous cases<ref>Methotrexate. (n.d.). UW Department of Orthopaedics and Sports Medicine - Patient Care. Retrieved March 10, 2011, from http://www.orthop.washington.edu/PatientCare/OurServices/Arthritis/Articles/Methotrexate.aspx </ref>. | ||
== Structural Features DHFR== | == Structural Features DHFR== | ||
